Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Eur Urol. 2018 Oct 6;75(1):176–183. doi: 10.1016/j.eururo.2018.09.009

Table 3 –

Post-SLND characteristics of 654 patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer

Variable Overall population
(n = 654; 100%)
Lymph nodes removed at SLND    26 (15–38)
Positive lymph nodes at SLND, n (%)
 0    62 (9)
 1  150 (23)
 2    92 (14)
 ≥3  350 (54)
PSA after SLND, ng/ml   0.3 (0.0–1.0)
PSA difference (after–pre), ng/ml  −1.4 (−2.8 to−0.3)
PSA response after SLND
(<0.2 ng/ml), n (%)
 No  368 (56)
 Yes  286 (44)
Undetectable PSA after SLND
(<0.1 ng/ml), n (%)
 No  456 (70)
 Yes  198 (30)

PSA = prostate-specific antigen; SLND = salvage lymph node dissection.

All values are medians (interquartile range) or frequencies (proportions).